• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Genelux Corporation

    3/28/25 4:29:17 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on March 28, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Genelux Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   77-0583529

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

       

    2625 Townsgate Road, Suite 230

    Westlake Village, California 91361

      91361
    (Address of Principal Executive Offices)   (Zip Code)

     

    2022 Equity Incentive Plan

    2022 Employee Stock Purchase Plan

    (Full titles of the plans)

     

    Thomas Zindrick, J.D.

    President and Chief Executive Officer

    Genelux Corporation

    2625 Townsgate Road, Suite 230

    Westlake Village, California 91361

    (805) 267-9889

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Jason L. Kent

    Christine S. Kim

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

           
    Large Accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by Genelux Corporation (the “Registrant”) for the purpose of registering (i) an additional 1,729,664 shares of Registrant’s Common Stock, par value $0.0001 per share (“Common Stock”), under the Registrant’s 2022 Equity Incentive Plan (the “2022 Plan”) pursuant to the provisions of the 2022 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 Plan and (ii) 345,932 additional shares of Common Stock under the Registrant’s 2022 Employee Stock Purchase Plan (the “2022 ESPP”) pursuant to the provisions of the 2022 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 ESPP.

     

    PART II

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

     

    The following documents filed by the registrant with the Securities and Exchange Commission (SEC) are incorporated by reference into this registration statement:

     

    ●the contents of the Registration Statements on Form S-8 previously filed with the Commission on January 26, 2023 and March 29, 2024;

     

    ●the registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025; and

     

    ●the description of the registrant’s common stock contained in the registrant’s registration statement on Form 8-A, filed with the SEC on January 23, 2023, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.16 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024.

     

    All reports and other documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this registration statement, except as so modified or superseded.

     

     
     

     

    Item 8. Exhibits.

     

    The exhibits to this Registration Statement are listed below:

     

    Exhibit

    Number

      Description
       
    4.1   Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-41599), filed with the SEC on January 30, 2023).
       
    4.2   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-41599), filed with the SEC on January 30, 2023).
       
    4.3   Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on August 29, 2022).
       
    4.4   Investors’ Rights Agreement, by and among the Registrant and AbbVie, Inc. and Aladar Szalay, Ph.D., dated January 2010 (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).
       
    4.5   Form of Warrant to Purchase Common Stock issued to WDC Fund I, dated September 2020 (incorporated herein by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).
       
    4.6   Form of Umbrella Agreement Regarding Family Investments (incorporated herein by reference to Exhibit 4.5 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).
       
    4.7   Form of Convertible Note Purchase Agreement under the Umbrella Agreement (incorporated herein by reference to Exhibit 4.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).
       
    4.8   Form of Representative’s Warrant (incorporated herein by reference to Exhibit 4.7 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on September 19, 2022).
         
    4.9   Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.8 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-41599), filed with the SEC on May 15, 2023).
       
    4.10   Letter Agreement Amending the Umbrella Agreements, by and among the Registrant and Existing Noteholders dated April 4, 2023 (incorporated by reference to Exhibit 4.10 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-41599), filed with the SEC on May 15, 2023).
         
    4.11   Form of Warrant to Purchase Common Stock issued on July 28, 2023 in connection with Converted Convertible Notes Payable (incorporated by reference to Exhibit 4.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-41599), filed with the SEC on August 14, 2023).
         
    4.12   Form of Warrant to Purchase Common Stock issued on August 1, 2023 in connection with Converted Convertible Notes Payable (incorporated by reference to Exhibit 4.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-41599), filed with the SEC on August 14, 2023).
         
    4.13   Form of Indenture (incorporated by reference to Exhibit 4.14 to the Registrant’s Registration Statement on Form S-3 (File No. 333-276847), filed with the SEC on February 2, 2024.
         
    4.14   Form of Common Stock Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.17 to the Registrant’s Registration Statement on Form S-3 (File No. 333-276847), filed with the SEC on February 2, 2024.

     

     

     

     

    4.15   Form of Preferred Stock Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.18 to the Registrant’s Registration Statement on Form S-3 (File No. 333-276847), filed with the SEC on February 2, 2024.
         
    4.16   Form of Debt Securities Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.19 to the Registrant’s Registration Statement on Form S-3 (File No. 333-276847), filed with the SEC on February 2, 2024.
         
    4.17   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-41599), filed with the SEC on May 24, 2024).
         
    5.1*   Opinion of Cooley LLP.
       
    23.1*   Consent of Weinberg & Company, P.A., independent registered public accounting firm.
       
    23.2*   Consent of Cooley LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (included on the signature page).
       
    99.1   Genelux Corporation 2022 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).
       
    99.2   Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Genelux Corporation 2022 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).
         
    99.3  

    Genelux Corporation, Inc. 2022 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).

       
    107*   Filing Fee Table.

     

    * Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Westlake Village, State of California, on March 28, 2025.

     

      GENELUX CORPORATION
         
      By: /s/ Thomas Zindrick, J.D.
        Thomas Zindrick, J.D.
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Thomas Zindrick, J.D and Matthew Pulisic, and each of them as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

             

    /s/ Thomas Zindrick, J.D.

     

    President, Chief Executive Officer and

    Chairman of the Board

      March 28, 2025
    Thomas Zindrick, J.D.   (Principal Executive Officer)    
             

    /s/ Matthew Pulisic

     

    Chief Financial Officer

      March 28, 2025
    Matthew Pulisic   (Principal Financial and Accounting Officer)    
             

    /s/ Mary Mirabelli

      Director   March 28, 2025
    Mary Mirabelli        
             

    /s/ John Smither

      Director   March 28, 2025
    John Smither        
             

    /s/ James L. Tyree

      Director   March 28, 2025
    James L. Tyree        
             

    /s/ John Thomas, Ph.D.

      Director   March 28, 2025
    John Thomas, Ph.D.        

     

     

     

    Get the next $GNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Genelux Corporation

      10-Q - GENELUX Corp (0001231457) (Filer)

      5/6/25 4:06:34 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Genelux Corporation

      10-K/A - GENELUX Corp (0001231457) (Filer)

      4/29/25 4:05:19 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Genelux Corporation

      S-8 - GENELUX Corp (0001231457) (Filer)

      3/28/25 4:29:17 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Genelux with a new price target

      Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

      10/29/24 6:26:41 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Genelux with a new price target

      ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

      8/28/24 7:46:18 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Genelux with a new price target

      H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00

      11/27/23 7:16:52 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GNLX
    Leadership Updates

    Live Leadership Updates

    See more

    $GNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

      WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   "The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase 3 registrational trial in resistant/refractory ovarian cancer, promising early lung cancer clinical data from our ongoing Phase 1b/2 study, and increasing patient enrollment in our U.S. Ph

      5/6/25 4:10:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

      WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursday, May 8, 2025. A webcast link for the event will be available at https://wsw.com/webcast/jmp65/gnlx/1693890. An archived replay will be available for a

      5/1/25 4:05:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates. "Our pr

      3/28/25 4:10:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation Announces New Chief Financial Officer

      WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec." Mr. Pulisic is an ac

      2/3/25 6:45:00 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:20 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:16 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smither John W bought 6,250 shares, increasing direct ownership by 90% to 13,170 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:18 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Genelux Corporation

      SC 13G - GENELUX Corp (0001231457) (Subject)

      10/25/24 9:45:20 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Genelux Corporation

      SC 13G/A - GENELUX Corp (0001231457) (Subject)

      10/22/24 4:12:19 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genelux Corporation

      SC 13G - GENELUX Corp (0001231457) (Subject)

      2/2/24 4:06:25 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP, Clinical Trial Operations Yu Yong sold $16,291 worth of shares (5,579 units at $2.92), decreasing direct ownership by 10% to 47,640 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:37 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Pharmaceutical Development Cappello Joseph sold $13,832 worth of shares (4,737 units at $2.92), decreasing direct ownership by 8% to 52,266 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:36 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zindrick Thomas sold $31,431 worth of shares (10,764 units at $2.92), decreasing direct ownership by 5% to 191,447 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:39 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

      Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

      6/10/24 12:35:45 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care